Valneva SE (NASDAQ:VALN - Get Free Report)'s share price fell 11.2% during trading on Friday . The company traded as low as $6.87 and last traded at $6.92. 79,836 shares traded hands during trading, an increase of 30% from the average session volume of 61,567 shares. The stock had previously closed at $7.79.
Separately, HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Valneva in a report on Friday, January 31st.
View Our Latest Report on VALN
The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business has a 50 day moving average price of $4.87 and a 200-day moving average price of $5.67. The company has a market cap of $569.23 million, a P/E ratio of -53.88 and a beta of 1.98.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. ABC Arbitrage SA bought a new stake in shares of Valneva in the 4th quarter valued at about $84,000. AlphaCentric Advisors LLC increased its position in Valneva by 33.7% during the third quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company's stock worth $717,000 after buying an additional 29,748 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after buying an additional 30,859 shares during the period. Institutional investors own 11.39% of the company's stock.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.